Justin B Echouffo-Tcheugui1, Oluseye Ogunmoroti2, Sherita H Golden3, Alain G Bertoni4, Morgana Mongraw-Chaffin4, Ambarish Pandey5, Chiadi E Ndumele2, Erin D Michos2. 1. From the Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland. Electronic address: jechouf1@jhmi.edu. 2. Division of Cardiology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland. 3. From the Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland. 4. Department of Epidemiology & Prevention, Wake Forest School of Medicine, Winston-Salem, North Carolina. 5. The Division of Cardiology, Department of Medicine, UT Southwestern Medical Center, Dallas, Texas.
Abstract
BACKGROUND: Although diabetes increases heart failure (HF) risk, it is unclear how various dysglycemia markers (hemoglobin A1C [HbA1C], fasting plasma glucose [FPG], homeostasis model assessment of insulin resistance, and fasting insulin) are associated with HF subtypes (HF with preserved ejection fraction [HFpEF] and HF with reduced ejection fraction [HFrEF]). We assessed the relation of markers of dysglycemia and risks of HFpEF and HFrEF. METHODS AND RESULTS: We included 6688 adults without prevalent cardiovascular disease who attended the first MESA visit (2000-2002) and were followed for incident hospitalized HF (HFpEF or HFrEF). Association of glycemic markers and status (normoglycemia, prediabetes, diabetes) with HFpEF and HFrEF were evaluated using adjusted Cox models. Over a median follow-up of 14.9 years, there were 356 HF events (145 HFpEF, 173 HFrEF, and 38 indeterminate HF events). Diabetes status conferred higher risks of HFpEF (hazard ratio [HR] 1.85, 95% confidence interval [CI] 1.57-2.68) and HFrEF (HR 2.02, 95% CI 1.38-2.97) compared with normoglycemia. Higher levels of FPG (≥126 mg/dL) and HbA1C (≥6.5%) were associated with similarly higher risks of HFpEF (HR for FPG 1.96, 95% CI 1.21-3.17; HR for HbA1C 2.00, 95% CI 1.20-3.31) and HFrEF (HR for FPG 1.84, 95% CI 1.18-2.88; HR for HbA1C 1.99, 95% CI 1.28-3.09) compared with reference values. Prediabetic range HbA1C (5.7%-6.4%) or FPG (100%-125 mg/dL), homeostasis model assessment of insulin resistance, and fasting insulin were not significantly associated with HFpEF or HFrEF. CONCLUSIONS: Among community-dwelling individuals, HbA1C and FPG in the diabetes range were each associated with higher risks of HFpEF and HFrEF, with similar magnitudes of their associations. LAY ABSTRACT: Heart failure (HF) has 2 major subtypes (the heart's inability to pump or to fill up). Diabetes is known to increase HF risk, but its effects and that of markers of high glucose levels (fasting blood glucose and hemoglobin A1C) on the occurrence of HF subtypes remains unknown. Among 6688 adults without known cardiovascular disease followed for nearly 15 years, diabetes conferred significantly higher risks of both HF types, compared with those with normal blood glucose levels. Higher levels of fasting blood glucose and hemoglobin A1C were similarly associated with higher risks of both types of HF.
BACKGROUND: Although diabetes increases heart failure (HF) risk, it is unclear how various dysglycemia markers (hemoglobin A1C [HbA1C], fasting plasma glucose [FPG], homeostasis model assessment of insulin resistance, and fasting insulin) are associated with HF subtypes (HF with preserved ejection fraction [HFpEF] and HF with reduced ejection fraction [HFrEF]). We assessed the relation of markers of dysglycemia and risks of HFpEF and HFrEF. METHODS AND RESULTS: We included 6688 adults without prevalent cardiovascular disease who attended the first MESA visit (2000-2002) and were followed for incident hospitalized HF (HFpEF or HFrEF). Association of glycemic markers and status (normoglycemia, prediabetes, diabetes) with HFpEF and HFrEF were evaluated using adjusted Cox models. Over a median follow-up of 14.9 years, there were 356 HF events (145 HFpEF, 173 HFrEF, and 38 indeterminate HF events). Diabetes status conferred higher risks of HFpEF (hazard ratio [HR] 1.85, 95% confidence interval [CI] 1.57-2.68) and HFrEF (HR 2.02, 95% CI 1.38-2.97) compared with normoglycemia. Higher levels of FPG (≥126 mg/dL) and HbA1C (≥6.5%) were associated with similarly higher risks of HFpEF (HR for FPG 1.96, 95% CI 1.21-3.17; HR for HbA1C 2.00, 95% CI 1.20-3.31) and HFrEF (HR for FPG 1.84, 95% CI 1.18-2.88; HR for HbA1C 1.99, 95% CI 1.28-3.09) compared with reference values. Prediabetic range HbA1C (5.7%-6.4%) or FPG (100%-125 mg/dL), homeostasis model assessment of insulin resistance, and fasting insulin were not significantly associated with HFpEF or HFrEF. CONCLUSIONS: Among community-dwelling individuals, HbA1C and FPG in the diabetes range were each associated with higher risks of HFpEF and HFrEF, with similar magnitudes of their associations. LAY ABSTRACT: Heart failure (HF) has 2 major subtypes (the heart's inability to pump or to fill up). Diabetes is known to increase HF risk, but its effects and that of markers of high glucose levels (fasting blood glucose and hemoglobin A1C) on the occurrence of HF subtypes remains unknown. Among 6688 adults without known cardiovascular disease followed for nearly 15 years, diabetes conferred significantly higher risks of both HF types, compared with those with normal blood glucose levels. Higher levels of fasting blood glucose and hemoglobin A1C were similarly associated with higher risks of both types of HF.
Authors: Orly Vardeny; Deepak K Gupta; Brian Claggett; Stuart Burke; Amil Shah; Laura Loehr; Laura Rasmussen-Torvik; Elizabeth Selvin; Patricia P Chang; David Aguilar; Scott D Solomon Journal: JACC Heart Fail Date: 2013-12 Impact factor: 12.035
Authors: Vishal N Rao; Di Zhao; Matthew A Allison; Eliseo Guallar; Kavita Sharma; Michael H Criqui; Mary Cushman; Roger S Blumenthal; Erin D Michos Journal: JACC Heart Fail Date: 2018-10-10 Impact factor: 12.035
Authors: Rudolf A de Boer; Matthew Nayor; Christopher R deFilippi; Danielle Enserro; Vijeta Bhambhani; Jorge R Kizer; Michael J Blaha; Frank P Brouwers; Mary Cushman; Joao A C Lima; Hossein Bahrami; Pim van der Harst; Thomas J Wang; Ron T Gansevoort; Caroline S Fox; Hanna K Gaggin; Willem J Kop; Kiang Liu; Ramachandran S Vasan; Bruce M Psaty; Douglas S Lee; Hans L Hillege; Traci M Bartz; Emelia J Benjamin; Cheeling Chan; Matthew Allison; Julius M Gardin; James L Januzzi; Sanjiv J Shah; Daniel Levy; David M Herrington; Martin G Larson; Wiek H van Gilst; John S Gottdiener; Alain G Bertoni; Jennifer E Ho Journal: JAMA Cardiol Date: 2018-03-01 Impact factor: 14.676
Authors: Andreas Kalogeropoulos; Vasiliki Georgiopoulou; Tamara B Harris; Stephen B Kritchevsky; Douglas C Bauer; Andrew L Smith; Elsa Strotmeyer; Anne B Newman; Peter W F Wilson; Bruce M Psaty; Javed Butler Journal: J Card Fail Date: 2009-04-25 Impact factor: 5.712
Authors: Darren K McGuire; Weichung J Shih; Francesco Cosentino; Bernard Charbonnel; David Z I Cherney; Samuel Dagogo-Jack; Richard Pratley; Michelle Greenberg; Shuai Wang; Susan Huyck; Ira Gantz; Steven G Terra; Urszula Masiukiewicz; Christopher P Cannon Journal: JAMA Cardiol Date: 2021-02-01 Impact factor: 14.676
Authors: Milton Packer; Javed Butler; Faiez Zannad; Gerasimos Filippatos; Joao Pedro Ferreira; Stuart J Pocock; Peter Carson; Inder Anand; Wolfram Doehner; Markus Haass; Michel Komajda; Alan Miller; Steen Pehrson; John R Teerlink; Sven Schnaidt; Cordula Zeller; Janet M Schnee; Stefan D Anker Journal: Circulation Date: 2021-08-29 Impact factor: 29.690
Authors: Tran Kim Son; Ngo Hoang Toan; Nguyen Thang; Huynh Le Trong Tuong; Hoang Anh Tien; Nguyen Hai Thuy; Huynh Van Minh; Paul Valensi Journal: Cardiovasc Diabetol Date: 2022-05-14 Impact factor: 8.949